514 related articles for article (PubMed ID: 20458086)
1. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection.
Howell MD; Novack V; Grgurich P; Soulliard D; Novack L; Pencina M; Talmor D
Arch Intern Med; 2010 May; 170(9):784-90. PubMed ID: 20458086
[TBL] [Abstract][Full Text] [Related]
2. Gastric acid suppression by proton pump inhibitors as a risk factor for clostridium difficile-associated diarrhea in hospitalized patients.
Aseeri M; Schroeder T; Kramer J; Zackula R
Am J Gastroenterol; 2008 Sep; 103(9):2308-13. PubMed ID: 18702653
[TBL] [Abstract][Full Text] [Related]
3. Differential risk of Clostridium difficile infection with proton pump inhibitor use by level of antibiotic exposure.
Stevens V; Dumyati G; Brown J; Wijngaarden E
Pharmacoepidemiol Drug Saf; 2011 Oct; 20(10):1035-42. PubMed ID: 21833992
[TBL] [Abstract][Full Text] [Related]
4. Proton pump inhibitors increase significantly the risk of Clostridium difficile infection in a low-endemicity, non-outbreak hospital setting.
Dalton BR; Lye-Maccannell T; Henderson EA; Maccannell DR; Louie TJ
Aliment Pharmacol Ther; 2009 Mar; 29(6):626-34. PubMed ID: 19183143
[TBL] [Abstract][Full Text] [Related]
5. Proton pump inhibitors as a risk factor for paediatric Clostridium difficile infection.
Turco R; Martinelli M; Miele E; Roscetto E; Del Pezzo M; Greco L; Staiano A
Aliment Pharmacol Ther; 2010 Apr; 31(7):754-9. PubMed ID: 20047577
[TBL] [Abstract][Full Text] [Related]
6. Incidence of Clostridium difficile infections in patients receiving antimicrobial and acid-suppression therapy.
King RN; Lager SL
Pharmacotherapy; 2011 Jul; 31(7):642-8. PubMed ID: 21923450
[TBL] [Abstract][Full Text] [Related]
7. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies.
Dial S; Alrasadi K; Manoukian C; Huang A; Menzies D
CMAJ; 2004 Jul; 171(1):33-8. PubMed ID: 15238493
[TBL] [Abstract][Full Text] [Related]
8. Proton pump inhibitors and risk for recurrent Clostridium difficile infection.
Linsky A; Gupta K; Lawler EV; Fonda JR; Hermos JA
Arch Intern Med; 2010 May; 170(9):772-8. PubMed ID: 20458084
[TBL] [Abstract][Full Text] [Related]
9. Proton Pump Inhibitors and the Risk for Hospital-Acquired Clostridium difficile Infection.
Barletta JF; El-Ibiary SY; Davis LE; Nguyen B; Raney CR
Mayo Clin Proc; 2013 Oct; 88(10):1085-90. PubMed ID: 24012413
[TBL] [Abstract][Full Text] [Related]
10. Fluoroquinolone use and risk factors for Clostridium difficile-associated disease within a Veterans Administration health care system.
McFarland LV; Clarridge JE; Beneda HW; Raugi GJ
Clin Infect Dis; 2007 Nov; 45(9):1141-51. PubMed ID: 17918075
[TBL] [Abstract][Full Text] [Related]
11. Clostridium difficile infection in an urban medical center: five-year analysis of infection rates among adult admissions and association with the use of proton pump inhibitors.
Jayatilaka S; Shakov R; Eddi R; Bakaj G; Baddoura WJ; DeBari VA
Ann Clin Lab Sci; 2007; 37(3):241-7. PubMed ID: 17709687
[TBL] [Abstract][Full Text] [Related]
12. Proton pump inhibitor therapy is a risk factor for Clostridium difficile-associated diarrhoea.
Yearsley KA; Gilby LJ; Ramadas AV; Kubiak EM; Fone DL; Allison MC
Aliment Pharmacol Ther; 2006 Aug; 24(4):613-9. PubMed ID: 16907893
[TBL] [Abstract][Full Text] [Related]
13. Recurrent community-acquired pneumonia in patients starting acid-suppressing drugs.
Eurich DT; Sadowski CA; Simpson SH; Marrie TJ; Majumdar SR
Am J Med; 2010 Jan; 123(1):47-53. PubMed ID: 20102991
[TBL] [Abstract][Full Text] [Related]
14. Acid-Suppressing Agents and Risk for Clostridium difficile Infection in Pediatric Patients.
Brown KE; Knoderer CA; Nichols KR; Crumby AS
Clin Pediatr (Phila); 2015 Oct; 54(11):1102-6. PubMed ID: 25644650
[TBL] [Abstract][Full Text] [Related]
15. Proton pump inhibitors and diarrhoea related to Clostridium difficile infection in hospitalised patients: a case-control study.
Leonard AD; Ho KM; Flexman J
Intern Med J; 2012 May; 42(5):591-4. PubMed ID: 22616966
[TBL] [Abstract][Full Text] [Related]
16. Proton pump inhibitors increase the risk for hospital-acquired Clostridium difficile infection in critically ill patients.
Barletta JF; Sclar DA
Crit Care; 2014 Dec; 18(6):714. PubMed ID: 25540023
[TBL] [Abstract][Full Text] [Related]
17. Proton pump inhibitor use and recurrent Clostridium difficile-associated disease: a case-control analysis matched by propensity score.
Kim YG; Graham DY; Jang BI
J Clin Gastroenterol; 2012; 46(5):397-400. PubMed ID: 22298089
[TBL] [Abstract][Full Text] [Related]
18. Potential influence of antisecretory therapy on the development of Candida-associated intraabdominal infection.
Cat TB; Charash W; Hebert J; Marden BT; Corbett SM; Ahern J; Rebuck JA
Ann Pharmacother; 2008 Feb; 42(2):185-91. PubMed ID: 18212256
[TBL] [Abstract][Full Text] [Related]
19. Use of Acid Suppression Medication is Associated With Risk for C. difficile Infection in Infants and Children: A Population-based Study.
Freedberg DE; Lamousé-Smith ES; Lightdale JR; Jin Z; Yang YX; Abrams JA
Clin Infect Dis; 2015 Sep; 61(6):912-7. PubMed ID: 26060292
[TBL] [Abstract][Full Text] [Related]
20. Risk of Clostridium difficile Infection with the Use of a Proton Pump Inhibitor for Stress Ulcer Prophylaxis in Critically Ill Patients.
Ro Y; Eun CS; Kim HS; Kim JY; Byun YJ; Yoo KS; Han DS
Gut Liver; 2016 Jul; 10(4):581-6. PubMed ID: 27021503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
